Hinterhaus Productions via Getty Images Shares of Edgewise Therapeutics fell sharply Wednesday after the company released data for its latest clinical trial. The drug accomplished its main goal ...

Edgewise Therapeutics (NASDAQ:EWTX) was downgraded to Sector Perform from prior Sector Outperform at Scotiabank after results from the company's mid-stage trial for its heart disease therapy EDG ...

Edgewise Therapeutics (NASDAQ:EWTX) fell 10.6% in premarket trade after it priced its offering to raise $200 million. The firm priced its underwritten offering of 9.9M shares at $20.13 apiece ...

Edgewise Therapeutics' hypertrophic cardiomyopathy (HCM) asset has resulted in “rapid and clinically meaningful” reductions of a measure of obstruction of the heart’s valves. The biotech has ...

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Edgewise Therapeutics Inc. (NASDAQ:EWTX) stands ...

April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other stocks that insiders bought in April after Trump’s tariff rollout.

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM. EDG-7500 is a novel oral ...

Also Read: Edgewise Therapeutics’ Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease In September 2024, the company announced topline data from ...

(RTTNews) - Edgewise Therapeutics (EWTX) reported positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic ...

Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a biopharmaceutical company that discovers, develops, and commercializes therapies to treat muscle disorders. Its lead product candidate, EDG-5506, is ...